by Truveta News | Feb 13, 2025 | Data
Truveta Data has now expanded to include new commercial, Medicare, and Medicaid closed claims on more than 200 million patients, linked with electronic health record (EHR) data for more than 120 million patients already part of Truveta Data. Truveta Data now provides...
by Truveta staff | Feb 4, 2025 | Data
The start of a new year can be a time for fresh beginnings and new resolutions. Yet for many, it also brings a renewed struggle with anxiety and depression. The cold, dark days of winter, combined with post-holiday stress and lingering financial pressures, can make...
by Truveta staff | Jan 9, 2025 | Data
In the world of medical research, data drives discovery. But until recently, nearly 80% of data relevant to research has been hidden in clinical notes. These notes include detailed observations, symptoms, and treatment plans that are absent from the structured data...
by Truveta staff | Dec 10, 2024 | Data
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity Health Electronic health record (EHR) data is rapidly changing how life sciences,...
by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
